353 related articles for article (PubMed ID: 18824337)
1. Discordance between receptor status in primary and metastatic breast cancer: an exploratory study of bone and bone marrow biopsies.
Amir E; Ooi WS; Simmons C; Kahn H; Christakis M; Popovic S; Kalina M; Chesney A; Singh G; Clemons M
Clin Oncol (R Coll Radiol); 2008 Dec; 20(10):763-8. PubMed ID: 18824337
[TBL] [Abstract][Full Text] [Related]
2. Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer.
Broom RJ; Tang PA; Simmons C; Bordeleau L; Mulligan AM; O'Malley FP; Miller N; Andrulis IL; Brenner DM; Clemons MJ
Anticancer Res; 2009 May; 29(5):1557-62. PubMed ID: 19443366
[TBL] [Abstract][Full Text] [Related]
3. Acquisition of metastatic tissue from patients with bone metastases from breast cancer.
Hilton JF; Amir E; Hopkins S; Nabavi M; DiPrimio G; Sheikh A; Done SJ; Gianfelice D; Kanji F; Dent S; Barth D; Bouganim N; Al-Najjar A; Clemons M
Breast Cancer Res Treat; 2011 Oct; 129(3):761-5. PubMed ID: 21113656
[TBL] [Abstract][Full Text] [Related]
4. Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancer.
Aurilio G; Monfardini L; Rizzo S; Sciandivasci A; Preda L; Bagnardi V; Disalvatore D; Pruneri G; Munzone E; Della Vigna P; Renne G; Bellomi M; Curigliano G; Goldhirsch A; Nolè F
Acta Oncol; 2013 Nov; 52(8):1649-56. PubMed ID: 23327413
[TBL] [Abstract][Full Text] [Related]
5. Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies.
Amir E; Clemons M; Purdie CA; Miller N; Quinlan P; Geddie W; Coleman RE; Freedman OC; Jordan LB; Thompson AM
Cancer Treat Rev; 2012 Oct; 38(6):708-14. PubMed ID: 22178456
[TBL] [Abstract][Full Text] [Related]
6. Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management.
Guarneri V; Giovannelli S; Ficarra G; Bettelli S; Maiorana A; Piacentini F; Barbieri E; Dieci MV; D'Amico R; Jovic G; Conte P
Oncologist; 2008 Aug; 13(8):838-44. PubMed ID: 18650259
[TBL] [Abstract][Full Text] [Related]
7. [Discordance of estrogen receptor (ER), progestin receptor (PR), and HER-2 receptor statuses between primary and metastatic focuses of breast cancer].
Wang B; Guan ZZ; Liu DG; Lin TY; Zhang L; Xia ZJ; Teng XY
Ai Zheng; 2004 Dec; 23(12):1710-3. PubMed ID: 15601567
[TBL] [Abstract][Full Text] [Related]
8. Expression of the calcium receptor in human breast cancer--a potential new marker predicting the risk of bone metastases.
Mihai R; Stevens J; McKinney C; Ibrahim NB
Eur J Surg Oncol; 2006 Jun; 32(5):511-5. PubMed ID: 16564154
[TBL] [Abstract][Full Text] [Related]
9. Pattern of metastatic spread in triple-negative breast cancer.
Dent R; Hanna WM; Trudeau M; Rawlinson E; Sun P; Narod SA
Breast Cancer Res Treat; 2009 May; 115(2):423-8. PubMed ID: 18543098
[TBL] [Abstract][Full Text] [Related]
10. Cyclo-oxygenase-2 (COX-2) mRNA expression and hormone receptor status in breast cancer.
McCarthy K; Bustin SA; Ogunkolade B; Khalaf S; Laban CA; McVittie CJ; Carpenter R; Jenkins PJ
Eur J Surg Oncol; 2006 Sep; 32(7):707-9. PubMed ID: 16650963
[TBL] [Abstract][Full Text] [Related]
11. Pulmonary metastases of breast cancer. When is resection indicated?
Welter S; Jacobs J; Krbek T; Tötsch M; Stamatis G
Eur J Cardiothorac Surg; 2008 Dec; 34(6):1228-34. PubMed ID: 18824371
[TBL] [Abstract][Full Text] [Related]
12. [Prevalence of elevated serum CA 15-3 at time of metastatic relapse of breast cancer and correlation with hormone receptor status].
Bensouda Y; André F; Boulet T; Al-Ghuzlan A; Conforti R; Troalen F; Bourgier C; Errihani H; Spielmann M; Delaloge S
Bull Cancer; 2009 Oct; 96(10):923-8. PubMed ID: 19696005
[TBL] [Abstract][Full Text] [Related]
13. Receptor expression discrepancy between primary and metastatic breast cancer lesions.
Karagöz Özen DS; Ozturk MA; Aydin Ö; Turna ZH; Ilvan S; Özgüroglu M
Oncol Res Treat; 2014; 37(11):622-6. PubMed ID: 25427579
[TBL] [Abstract][Full Text] [Related]
14. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan.
Sharif MA; Mamoon N; Mushtaq S; Khadim MT
J Coll Physicians Surg Pak; 2009 Feb; 19(2):99-103. PubMed ID: 19208313
[TBL] [Abstract][Full Text] [Related]
15. Discordance in early breast cancer for tumour grade, estrogen receptor, progesteron receptors and human epidermal receptor-2 status between core needle biopsy and surgical excisional primary tumour.
Lorgis V; Algros MP; Villanueva C; Chaigneau L; Thierry-Vuillemin A; Nguyen T; Demarchi M; Bazan F; Sautiere JL; Maisonnette-Lescot Y; Ringenbach F; Bontemps P; Pivot X
Breast; 2011 Jun; 20(3):284-7. PubMed ID: 21288720
[TBL] [Abstract][Full Text] [Related]
16. Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours-a review.
Yeung C; Hilton J; Clemons M; Mazzarello S; Hutton B; Haggar F; Addison CL; Kuchuk I; Zhu X; Gelmon K; Arnaout A
Cancer Metastasis Rev; 2016 Sep; 35(3):427-37. PubMed ID: 27405651
[TBL] [Abstract][Full Text] [Related]
17. Incidence of pathologic complete response in women treated with preoperative chemotherapy for locally advanced breast cancer: correlation of histology, hormone receptor status, Her2/Neu, and gross pathologic findings.
Alvarado-Cabrero I; Alderete-Vázquez G; Quintal-Ramírez M; Patiño M; Ruíz E
Ann Diagn Pathol; 2009 Jun; 13(3):151-7. PubMed ID: 19433292
[TBL] [Abstract][Full Text] [Related]
18. [Effect of neoadjuvant chemotherapy on estrogen and progesterone receptors and P53 and CerbB-2 in breast cancer].
Bao G; Yang DQ; Zhou B; Liu P; Wang S; Cheng L
Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(40):2843-5. PubMed ID: 18167290
[TBL] [Abstract][Full Text] [Related]
19. Comparative analysis of bone marrow micrometastases with sentinel lymph node status in early-stage breast cancer.
Saha S; Ali S; Ghanem M; Soni M; Wiese D; Arora M; Singh T; Iddings D
Ann Surg Oncol; 2009 Feb; 16(2):276-80. PubMed ID: 19050967
[TBL] [Abstract][Full Text] [Related]
20. Changes in tumour biological markers during primary systemic chemotherapy (PST).
Neubauer H; Gall C; Vogel U; Hornung R; Wallwiener D; Solomayer E; Fehm T
Anticancer Res; 2008; 28(3B):1797-804. PubMed ID: 18630463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
